Vimarsana
Biggest News Aggregation in the World

Stop Read News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stop Read. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stop Read Today - Breaking & Trending Today

New Insights: B Cell-Derived Natural Antibodies Suppress Autoimmune Pathogenesis in Type 1 Diabetes - Vimarsana News

New Insights: B Cell-Derived Natural Antibodies Suppress Autoimmune Pathogenesis in Type 1 Diabetes

Researchers have discovered the novel mechanism that underlies a previously reported observation that infection by group A Streptococcus bacteria reduces the risk of later developing Type 1 diabetes.The Journal of Immunology reports that vaccination

Type 1 diabetes: B cell-derived natural antibodies suppress autoimmune pathogenesis - Vimarsana News

Type 1 diabetes: B cell-derived natural antibodies suppress autoimmune pathogenesis

Vaccination of neonatal mice with group A Streptococcus promotes clonal expansion of B cells that produce antibody against GlcNAc. The association of reduced Type 1 diabetes risk after group A Streptococcus infection is...

Source: uab.edu
UCalgary researchers discover how Leishmania parasites hide within the body - Vimarsana News

UCalgary researchers discover how Leishmania parasites hide within the body

University of Calgary researchers have discovered how Leishmania parasites hide within the body to cause Leishmaniasis. The tiny parasites are carried by infected sand flies.

OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases an - Vimarsana News

OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases an

OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology·        Positive Phase 1 clinical results published in 'The Journal of Immunology’ (online)· &...

OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology - Vimarsana News

OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology

Positive Phase 1 clinical results published in 'The Journal of Immunology' (online) Two ongoing Phase 2 clinical trials in Ulcerative Colitis and primary Sjögren's Syndrome Positive